Lahn, Michael M. F.

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

Melisi, D., Garcia-Carbonero, R., Macarulla, T., Pezet, D., Deplanque, G., Fuchs, M., Trojan, J., Oettle, H., Kozloff, M., Cleverly, A., et al. (2018) · British Journal of Cancer

Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and Treatment

Cited by 294

A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma

Brandes, A. A., Carpentier, A. F., Kesari, S., Sepulveda-Sanchez, J. M., Wheeler, H. R., Chinot, O., Cher, L., Steinbach, J. P., Capper, D., Specenier, P., et al. (2016) · Neuro-Oncology

Glioma Diagnosis and TreatmentOvarian cancer diagnosis and treatment

Cited by 273

Phase 1b study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer

Ikeda, M., Takahashi, H., Kondo, S., Lahn, M. M. F., Ogasawara, K., Benhadji, K. A., Fujii, H., & Ueno, H. (2017) · Cancer Chemotherapy and Pharmacology

Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and Treatment

Cited by 51

Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer

Oxnard, G. R., Ramalingam, S. S., Ahn, M.-J., Kim, S.-W., Yu, H. A., Saka, H., Horn, L., Goto, K., Ohe, Y., Cantarini, M., et al. (2015) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 46

A phase 1b study of transforming growth factor‐beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma

Ikeda, M., Morimoto, M., Tajimi, M., Inoue, K., Benhadji, K. A., Lahn, M. M. F., & Sakai, D. (2019) · Investigational New Drugs

Hepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and Studies

Cited by 46